Cell Therapy News Volume 24.14 | Apr 24 2023

    By
    Jamie Kang
    -
    0
    17







    2023-04-24 | CTN 24.14


    Cell Therapy News by STEMCELL Technologies
    Vol. 24.14 – 24 April, 2023
    TOP STORY

    Downregulation of the RNA-Binding Protein PUM2 Facilitates MSC-Driven Bone Regeneration and Prevents OVX-Induced Bone Loss

    Scientists suggested a novel role for PUMILIO2 (PUM2) in MSC osteogenesis and highlighted the potential of PUM2 knockdown-MSCs in bone regeneration. Additionally, they showed that AAV9-siPum2 is a potential gene therapy for osteoporosis.
    [Journal Of Biomedical Science]

    Full Article
    Survey results on the insights and hurdles of CRISPR genome editing.
    PUBLICATIONSRanked by the impact factor of the journal

    Which One Is Better for Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia: Single-Target (CD19) or Dual-Target (Tandem or Sequential CD19/CD22) CAR T-Cell Therapy?

    Investigators screened 219 patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were enrolled in clinical trials of either CD19 or CD19/CD22 CAR T-cell therapy.
    [Blood Cancer Journal]

    Full Article

    Early Lymphocyte Collection for Anti-CD19 CART Production Improves T-Cell Fitness in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Scientists conducted a prospective study and evaluated the potential benefit of an earlier lymphopheresis on the clinical outcome of CD19-CART infused DLBCL patients, in comparison with standard lymphopoiesis.
    [British Journal Of Haematology]

    Full Article

    Intrinsic Tumor Resistance to CAR T Cells Is a Dynamic Transcriptional State That Is Exploitable With Low-Dose Radiation

    Researchers found that substantially reducing systemic tumor quantity using high-dose radiation to bulky disease, which is commonly done clinically, was less impactful on overall survival in mice achieved by CAR T cells than targeting all sites of disease with low-dose total tumor radiation prior to CAR T-cells.
    [Blood Advances]

    Abstract

    Human iPSC-Derived Neural Progenitor Cells Secreting GDNF Provide Protection in Rodent Models of ALS and Retinal Degeneration

    Neural progenitor cells transduced with glial cell line-derived neurotrophic factors were transplanted into the subretinal space of rats where they protected photoreceptors and vision, and the spinal cord of SOD1 rats where they protected motor neurons.
    [Stem Cell Reports]

    Full ArticleGraphical Abstract

    Bruton Tyrosine Kinase Inhibitors Preserve Anti-CD19 Chimeric Antigen Receptor T Cell Functionality and Reprogram Tumor Micro-Environment in B-Cell Lymphoma

    Researchers revealed that Bruton tyrosine kinase inhibitors (BTKIs) preserved T-cell and CART19 functionality under persistent antigen exposure and further demonstrated that BTKI administration was a potential strategy for mitigating cytokine release syndrome after CART19 treatment.
    [Cytotherapy]

    Full Article

    Safety and Efficacy of Mesenchymal Stromal Cell Therapy for Multi-Drug-Resistant Acute and Late-Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

    Scientists presented a multicenter study on the safety and efficacy of MSC therapy for patients with steroid-refractory late steroid-refractory acute graft versus host disease (aGvHD) in comparison to those with aGvHD.
    [Annals Of Hematology]

    Abstract

    DC Vaccine Enhances CAR-T Cell Antitumor Activity by Overcoming T Cell Exhaustion and Promoting T Cell Infiltration in Solid Tumors

    Investigators demonstrated that dendritic cell (DC) vaccines could promote CAR-T therapy in solid tumors, which provided the possibility of widespread clinical application of CAR-T cells in the future.
    [Clinical And Translational Oncology]

    Abstract

    Adipose-Derived Human Mesenchymal Stem Cells Seeded on Denuded or Stromal Sides of the Amniotic Membrane Improve Angiogenesis and Collagen Remodeling and Accelerate Healing of the Full-Thickness Wound

    Researchers investigated the feasibility and effectiveness of wound healing using decellularized HAM and stromal HAM (sAM) in combination with adipose-derived human mesenchymal stem cells (AdMSCs), and found that the combination promoted wound healing by enhancing angiogenesis and collagen remodeling.
    [Acta Histochemica]

    Abstract
    This webinar provides insights and techniques for efficient leukopak sample processing and streamlined cell isolation.
    REVIEWS

    Advancing Cell Therapy for Neurodegenerative Diseases

    The authors examine how the ability to generate diverse central nervous system cell types from stem cells, along with a deeper understanding of cell-type-specific functions and pathology, is advancing preclinical development of cell products for the treatment of neurodegenerative diseases.
    [Cell Stem Cell]

    Abstract

    Mechanisms of Resistance and Treatment of Relapse After CAR T-Cell Therapy for Large B-Cell Lymphoma and Multiple Myeloma

    Focusing on both large B cell lymphoma and multiple myeloma, investigators review resistance mechanisms, explore therapeutic avenues to overcome resistance to CAR T cell therapies, and discuss the management of patients who have relapsed after CAR T cell therapy.
    [Transplantation And Cellular Therapy]

    Abstract
    INDUSTRY AND POLICY NEWS

    Medigene Presents Final Phase I Data of TCR-T Cell Therapy MDG1011 in Patients With High-Risk Blood Cancers

    Medigene AG reported final Phase I dose escalation results from the first-in-human study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy for high-risk myeloid and lymphoid neoplasms.
    [Medigene AG]

    Press Release
    FEATURED EVENT

    Understanding Cell Behavior and Communication

    April 30 – May 5, 2023
    Barga, Italy

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Modeling Allogeneic Cell Therapy Processes

    Delft University of Technology – Delft, Netherlands

    Research Associate – CAR T Cell Immune Therapies for Cancer

    Imperial College London – London, England, United Kingdom

    Faculty Positions – Cancer Research

    Case Western Reserve University – Cleveland, Ohio, United States

    Specialist – Cell Processing

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Research Associate – CAR T Cell Immune Therapies

    Imperial College London – London, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter